�鶹��ý

In testimony presented to a U.S. House of Representatives Judiciary subcommittee the �鶹��ý Trade Commission described its ongoing efforts to protect competition and consumers in many important...

The �鶹��ý Trade Commission has asked the U.S. District Court for the District of New Jersey to accept an amicus brief that addresses the application of the U.S. Supreme Court’s recent ruling in FTC...

The �鶹��ý Trade Commission told a Senate Judiciary subcommittee today that it will continue to challenge anticompetitive pay-for-delay court settlements in the pharmaceutical industry, and that the...

�鶹��ý Trade Commission Chairwoman Edith Ramirez issued the following statement regarding today's decision by the U.S. Supreme Court in FTC v. Actavis, Inc., which held that pay-for-delay agreements...

�鶹��ý Trade Commission Chairwoman Edith Ramirez released the agency’s 2012-2013 Annual Highlights today at the Spring Meeting of the American Bar Association’s Section of Antitrust Law in Washington...

In Fiscal Year (FY) 2012, the number of potentially anticompetitive patent dispute settlements between branded and generic drug companies increased significantly compared with FY 2011, jumping from 28...

In testimony today before a U.S. House of Representatives Judiciary Subcommittee, the �鶹��ý Trade Commission detailed its work to promote competition and benefit consumers, including preventing...

FTC Files Amicus Brief in Support of Rehearing of Ciprofloxacin "Pay-for-Delay" Case The �鶹��ý Trade Commission has filed an amicus brief in the U.S. Court of Appeals for the Second Circuit...

�鶹��ý Trade Commission Chairman Jon Leibowitz issued the following statement regarding today’s decision by the U.S. Court of Appeals for the Second Circuit, which invited the plaintiffs in the...

Today’s decision seems to reflect a growing understanding—first in Congress now in the courts—that brand name drug companies must not be allowed to make pay-offs to their generic competitors to keep...

The �鶹��ý Trade Commission will continue working on behalf of Americans who are struggling to pay for their health care. According to our economic estimates, consumers would pocket about $3.5...

“When drug companies agree not to compete, consumers lose,” said �鶹��ý Trade Commission Chairman Jon Leibowitz. “Ending pay-for-delay settlements will help control drug costs. We’re delighted about...

�鶹��ý Trade Commission Chairman Jon Leibowitz and key members of Congress, including Representative Chris Van Hollen, Chairman Bobby Rush, and Representative Mary Jo Kilroy, today renewed their call...

By taking this action, the Committee clearly recognizes the very real danger that these sweetheart deals pose to Americans struggling to pay their medical bills. Consumers must wait – sometimes years...

I commend the House Energy and Commerce Committee for adopting the Protecting Consumer Access to Generic Drugs Act (H.R.1706) as an amendment to the omnibus health reform legislation. If enacted into...

In a speech today before the Center for American Progress in Washington, D.C., �鶹��ý Trade Commission Chairman Jon Leibowitz said that an internal FTC analysis projects that stopping collusive “pay...

Testifying today on behalf of the �鶹��ý Trade Commission before the U.S. House Judiciary Committee’s Subcommittee on Courts and Competition Policy, Bureau of Competition Director Richard A...